United States LYNPARZA Drug Insight and Market Forecast - 2032

“LYNPARZA Drug Insight and Market Forecast - 2032” report provides comprehensive insights about LYNPARZA for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the LYNPARZA for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019-2032 is provided in this report along with a detailed description of the LYNPARZA for ER+ve HER2-ve Breast Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LYNPARZA market forecast, analysis for ER+ve HER2-ve Breast Cancer in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in ER+ve HER2-ve Breast Cancer.

Drug Summary

LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. It is used in patients with deleterious or suspected deleterious gBRCAm, HR+ HER2− metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with HR+ breast cancer can also be treated with prior endocrine therapy or be considered inappropriate for endocrine therapy. This drug is also used as a first-line maintenance treatment of BRCA-mutated advanced ovarian cancer. LYNPARZA (Olaparib) is now indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm HER2− high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients will be selected for treatment based on an FDA-approved companion diagnostic test for LYNPARZA (Olaparib).

Dosage and Administration

• The recommended dose of LYNPARZA is 300 mg (two 150 mg tablets) taken orally twice daily, with or without food, for a total daily dose of 600 mg. The 100 mg tablet is available for dose reduction.
• If a patient misses a dose of LYNPARZA, instruct the patient to take their next dose at the scheduled time. Treatment should be continued until disease progression or unacceptable toxicity.
• If adverse events occur, then the dose should be reduced to 250 mg (one 150 mg tablet and one 100 mg tablet) taken twice daily, for a total daily dose of 500 mg.

Mechanism of Action

LYNPARZA is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes. PARP enzymes are involved in normal cellular functions such as DNA transcription and DNA repair. Olaparib has been shown to inhibit the growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer, both as monotherapy and following platinum-based chemotherapy.

Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA and non-BRCA proteins involved in the homologous recombination repair (HRR) of DNA damage and correlated with the platinum response. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increase the formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the LYNPARZA description, mechanism of action, dosage and administration, research and development activities in ER+ve HER2-ve Breast Cancer.
• Elaborated details on LYNPARZA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the LYNPARZA research and development activity in ER+ve HER2-ve Breast Cancer in detail across the United States.
• The report also covers the patents information with expiry timeline around LYNPARZA.
• The report contains forecasted sales of LYNPARZA for ER+ve HER2-ve Breast Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ER+ve HER2-ve Breast Cancer.
• The report also features the SWOT analysis with analyst views for LYNPARZA in ER+ve HER2-ve Breast Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LYNPARZA Analytical Perspective

In-depth LYNPARZA Market Assessment

This report provides a detailed market assessment of LYNPARZA in ER+ve HER2-ve Breast Cancer in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

LYNPARZA Clinical Assessment

The report provides the clinical trials information of LYNPARZA in ER+ve HER2-ve Breast Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for ER+ve HER2-ve Breast Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LYNPARZA dominance.
• Other emerging products for ER+ve HER2-ve Breast Cancer are expected to give tough market competition to LYNPARZA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LYNPARZA in ER+ve HER2-ve Breast Cancer.
• This in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LYNPARZA in ER+ve HER2-ve Breast Cancer.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of LYNPARZA?
• What is the clinical trial status of the study related to LYNPARZA in ER+ve HER2-ve Breast Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LYNPARZA development?
• What are the key designations that have been granted to LYNPARZA for ER+ve HER2-ve Breast Cancer?
• What is the forecasted market scenario of LYNPARZA for ER+ve HER2-ve Breast Cancer?
• What are the forecasted sales of LYNPARZA in the United States?
• What are the other emerging products available in ER+ve HER2-ve Breast Cancer and how are they giving competition to LYNPARZA for ER+ve HER2-ve Breast Cancer?
• Which are the late-stage emerging therapies under development for the treatment of ER+ve HER2-ve Breast Cancer?

This product will be delivered within 2 business days.